Interpretation of drug testing results requires detailed scientific information, particularly in those cases where the question of legitimate use versus illicit use arises. Amphetamine remains a widely abused drug throughout the world, although it is also used therapeutically for weight loss, narcolepsy, and attention-deficit disorder with hyperactivity (ADHD). Treatment of ADHD using stimulant drugs is much more common now than it was in even the recent past. Increasingly, older individuals are diagnosed and treated for ADHD, and treatment often continues into adulthood. Amphetamine is commonly used for the treatment of ADHD and is available by prescription as either the d-enantiomer or a mixture of enantiomers. Although used for many years, there are no data available to describe the excretion profile of amphetamine and its enantiomers following repeated use of the drug. As a result, medical review officers (MROs) and forensic toxicologists have no direct evidence to base their decisions on when it comes to evaluation of use of these drugs. The current study was designed to determine the concentration and enantiomer excretion profile following repeated daily administration of mixed enantiomers of amphetamine. Twenty milligrams of Adderall was administered daily to five healthy subjects with all subsequent ad lib urine samples collected for at least five days following administration of the five-dose regimen. Adderall is a 3:1 mixture of d-and I. enantiomers of amphetamine salts and represents the mixed enantiomer proportion of amphetamine available in the United States through pharmaceutical channels. Peak amphetamine concentrations ranged from 5739 to 19,172 ng/mL. Samples containing _> 500 ng/mL amphetamine (the administrative cutoff for a positive result by gas chromatography-mass spectrometry) were seen up to 60:15 (h:min) following administration of the last dose. Enantiomer analysis showed the d-enantiomer to be in excess of the I-enantiomer for as long as the drug was administered. After administration of the last dose of drug, the proportion of I-enantiomer increased over time. Not all samples that contained
Introduction
Medical use of amphetamine has a long history. Currently approved clinical indications for the use of amphetamine include narcolepsy, attention-deficit disorder with hyperactivity (ADHD), and as a short-term adjunct to a weight-reduction program. Because of tolerance and the significant potential for abuse, use of amphetamines as part of a weight-reduction program is limited in scope, and, when prescribed, the duration of treatment is generally limited to weeks rather than being a long-term treatment. The use of amphetamine for the treatment of narcolepsy and ADHD are long-standing uses and, unlike the weight-reduction regimen, are often prescribed on a chronic basis. The use of amphetamines for ADHD is common medical practice and can involve dextroamphetamine, dextromethamphetamine, or mixed isomer salts of amphetamine (1).
Amphetamines have a clearly recognized high abuse potential. Sources of the abused amphetamine include diversion of pharmaceutical amphetamine and illicit synthesis. The presence of a single asymmetric center gives rise to two possible enantiomers, most commonly referred to as d-and l-IS(+) and R(-) are also used to describe these enantiomers, respectively].
Many studies investigating the metabolism and factors that influence metabolism and excretion of amphetamines were completed in the 1960s and 1970s (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Several studies examined the effect of pH by administering agents to maintain acid or alkaline urine, which can be contrasted to uncontrolled conditions (6, 8, 12, 14, 15) . Results of these studies demonstrated that little of the drug is reabsorbed from the filtrate under acid conditions and was, therefore, excreted more rapidly. The opposite result was observed under alkaline conditions, in which more of the drug was reabsorbed. This results in lower concentrations of the drug in the urine and increased metabolism of the drug. One report showed averages of 54.5% of a 10-15-mg dose of amphetamine was excreted intact in 16 h under acid conditions, but only an average of 2.9% was excreted intact when the urine was maintained at an alkaline pH (15) .
Differences in the metabolism of amphetamine enantiomers have been investigated by a number of investigators (8, 12, 14, 16) . These studies were constrained by a number of factors that limit their use in interpretation of individual samples, as described in the present study. Despite these limitations, these studies demonstrated the d-enantiomer is metabolized more rapidly than the l-, causing the proportion of /-amphetamine to increase in the urine over time following the administration of racemic amphetamine.
The purpose of the present study is to examine the excretion profile of amphetamine following daily administration of the drug Adderall. Adderall is a single-entity (amphetamine) product composed of d-amphetamine saccharate, d,l-amphetamine aspartate, d-amphetamine sulfate, and d,l-amphetamine sulfate. The drug is available in 5-, 7.5-, 10-, 12.5-, 15-, 20-, and 30-rag tablets, as well as extended-release capsules. Adderall is designed to provide slow onset and offset, thus minimizing potential undesirable effects and the potential for abuse. It also often provides effective control of ADHD with a single daily dose, eliminating the necessity of dosing during the school or work day, making it a popular option of the drugs available to treat this condition. The target dosage of Adderall, as with most stimulant drugs, is the lowest effective dose. Initial recommended dosing for adults is typically 10 rag, followed by monitoring for effect and escalating the dose if necessary to get the desired effect. Typical adult ADHD patients are treated twice a day with 20 mg of the drug.
Materials and Methods

Materials
Amphetamine, methamphetamine, amphetamine-d6 (1- 2,3,3-ds) , and d,l-methamphetamine-d5 (1-phenyl-2-methyl-d3-aminopropane-l,2-d2) were obtained from Cerilliant (Austin, TX). Heptafluorobutyric anhydride (HFBA) was 
Drug administration and sample collection
Twenty-milligram doses of Adderall (equivalent to approximately 9.6 and 3.1 mg of d-and l-amphetamine base, respectively, per dose) in the form of a single tablet was administered to five healthy male volunteers on each of five consecutive days. Subjects ranged in age from the early 30's to 50's and had no history of drug abuse. The initial dose was administered in the morning. Subjects were instructed to administer subsequent doses at the same time on successive days. A pre-dose urine sample was collected from each subject to ensure no interfering substances were present. Urine samples were collected for each day of drug administration and the next five days. Samples were collected ad lib in order to best simulate what would be seen in random drug testing. Likewise, no attempt was made to physiologically control urine pH to best emulate the situation normally encountered in sample collection for random drug testing. Once collected, the samples were refrigerated until analysis.
Sample preparation and analysis
Sample pH was measured using a Fisher Accumet 50 pH meter (Houston, TX) and specific gravity determined using an AO Scientific Instruments (Keene, NY) refractometer. Creatinine levels were determined at the Wilford Hall Medical Center clinical laboratory using standard clinical laboratory procedures. Immunoassay analysis was accomplished using Roche Diagnostics Corporation On-Line reagents on an Olympus AU800 (Melville, NY) automated analyzer using standard procedures. Gas chromatographic-mass spectrometric (GC-MS) analyses were performed using a Hewlett-Packard (Agilent, Palo Alto, CA) 6890 GC coupled with an IIP 5973 MS using a 7683 autoinjector.
Quantitative analysis. Two-milliliter aliquots were extracted, derivatized with heptafluorobutyric anhydride (HFBA), and analyzed by GC-MS, as previously described (17) , with the additional option of using a ZB-50 (DB-17 equivalent) capillary column (15 m x 0.25-mm i.d., 0.25-1Jm film thickness) (Phenomenex, Torrance, CA), as well as the HP-1 column (12 m x 0.2-ram i.d., 0.33-1Jm film thickness). Instrumental conditions were as follows: splitless injection with injection port and interface temperatures at 270~ Conditions for the HP-1 consisted of a temperature program with an initial time of 1 rain at 80~ programmed to 180~ at 20~ a with a 2-rain final time. Conditions for the ZB-50 column consisted of a temperature program with an initial time of 2 rain at 80~ programmed to 125~ at 20~ then programmed to 150~ at 25~ with a final time of 0. Quantitation was based on single-point calibration using a calibration standard containing 500 ng/mL amphetamine and methamphetamine with 500 ng/mL deuterium-labeled isotopomer internal standards. Low concentration samples were quantitated based on single-point calibration using a standard at 25 ng/mL amphetamine and methamphetamine and with 50 ng/mL of each internal standard. Detection limits for this assay were 5 ng/mL for amphetamine and methamphetamine. The assay is linear to 10,000 ng/mL for amphetamine and methamphetamine, with a limit of quantitation (LOQ) of 5 ng/mL for both amphetamine and methamphetamine. Ions monitored were m/z 240, 118, 91 for amphetamine; m/z 254, 210, 118 for methamphetamine; m/z 244, 123 for amphetamine-d6; and m/z 260, 213 for methamphetamine-dll. Acceptance criteria were quantitative values within + 20% of the target concentration with proper qualitative identification as determined by ion ratios within + 20% and retention time within • 2% of the calibration standard while exhibiting acceptable chromatography.
Enantiomer analysis. Two-milliliter urine samples containing 500 ng/mL each of amphetamine-d5 and methamphetamine-ds were extracted and derivatized with I-TPC, as previously described (18) . Instrumental conditions were as follows: splitless injection, with injection port and interface temperatures set at 270~ Conditions for the HP-1 column (12 m x 0.2-mm i.d., 0.33-1Jm film thickness) consisted of a temperature program with initial temperature at 130~ programmed to 170~ at 4~ then to 240~ at 35~ with a final time of 0. Given that Adderall is amphetamine only, the run time for sample analysis was modified after elution of amphetamine to decrease overall run time. Ions monitored were m/z 237, 241, 251,255 for d-and/-amphetamine, d,l -amphetamine-ds; d-and l-methamphetamine and d,l-methamphetamine-ds, respectively. This assay was developed to provide qualitative determination of the enantiomeric composition of amphetamine, methamphetamine, and related analogues. Each batch of samples was calibrated using a sample containing 50% of both enantiomers of amphetamine and methamphetamine and analyzed with control samples containing 0% l-enantiomer plus 100% d-enantiomer of amphetamine and methamphetamine and 100% l-enantiomer plus 0% d-enantiomer of amphetamine and methamphetamine, along with a control containing no amphetamine or methamphetamine. Acceptance criteria were enantiomer ratios of the deuterated internal standards for all control and unknown samples within • 20% of calibrator, drug enantiomer ratios of controls within + 20% of target percentages, and negative control (0 ng/mL) showed no detectable amphetamine or methamphetamine, with acceptable chromatography and retention times within + 2% of calibrator.
Results and Discussion
Samples collected from subjects in this study (Table I) showed peak levels ranging from 5739 to 19,172 ng/mL. The first sample provided by each subject contained amphetamine at concentrations over 500 ng/mL (the administrative cutoff for a positive result by GC-MS). This is consistent with the results of a previous study using a single dose of this drug (19) . Samples containing ___ 500 ng/mL amphetamine were seen up to 60:15 (h:min) following administration of the last dose of the drug. Peak concentrations were reached anywhere from 6:45 to 108:00 h after the administration of the first dose. During the time, subjects were administered drug on a daily basis, nearly all individual samples were positive for amphetamine. These results suggest that individuals on a routine regimen of this drug will very likely test positive for amphetamine. However, not all samples that contained _ 500 ng/mL of amphetamine were positive by immunoassay. This is consistent, given the crossreactivity of the immunoassay reagents to racemic amphetamine (62%) and the l-enantiomer (5%) compared to 100% for d-amphetamine (20) . Amphetamine could be detected [limit of detection (LOD) = 5 ng/mL] in at least one subject, up to approximately 167 h following the last dose, which is comparable to the detection time following a single dose of the drug (19) .
Results of a study involving a single 20-mg dose showed peak levels ranging from 2645 to 5948 ng/mL. Peak concentrations were reached from 5:25 to 22:00 h following administration of the drug (19) . As seen in the current study, the first sample provided by each subject contained amphetamine at concentrations over 500 ng/mL.
As expected, the urine concentration of amphetamine was greatly effected by urine pH. Amphetamine concentrations also varied because of dilution of the urine as reflected by creatinine and specific gravity concentrations. The effects of pH change and creatinine concentration on the concentration of amphetamine are revealed by review of Table I , confirming the difficulty of assessing dose or time since dose based on concentration. Contrasting the extensive variability seen in drug concentrations, the enantiomer proportions were much more consistent and predictable despite changes in specific gravity, creatinine, and pH. The 3:1 ratio of d-to/-amphetamine in the tablet is reflected in the proportion of enantiomers found in the first urine samples collected following administration of the drug that showed 23.47 + 1.42%/-amphetamine. Following the first sample, the proportion of/-amphetamine increased with time until administration, and subsequent absorption, of the second dose, which resulted in a decrease in proportion of l-enantiomer. This change in proportion was repeated with each subsequent administration of the drug until after the last dose, when the proportion of lenantiomer continued to increase over time. This pattern of enantiomer proportions reflects the metabolism of the drug rather than its rate of excretion (influenced by pH) or volume of urine excretion (reflected by creatinine and specific gravity). These results are consistent with previous studies that show enantiomer ratios are not influenced by pH changes (6) and further supported by another study that evaluated pH, creatinine, and specific gravity effects (19) .
Amphetamine from pharmaceutical sources in the U.S. is either only d-amphetamine or a mixture of d-and/-amphetamine (1,21) and is not available as/-amphetamine alone. Currently available mixed enantiomer amphetamines in the U.S. are manufactured in the ratio of 3:1 d-to l-enantiomer. 9 Only a single sample is presented following the last detected amphetamine for each subject. All samples for each of the subjects collected after that time contained no detectable (_> 5 ng!mL) amphetamine. NA indicates enantiomer analysis was not completed because of the low concentration or lack of drug in the sample. Hours post dose represents time since administration of first dose. Subsequent doses administered at daily intervals. Immunoassay result is indicated as POS if the result was positive; all other samples tested negative by immunoassay. * Only a single sample is presented following the last detected amphetamine for each subject. All samples for each of the subjects collected after that time contained no detectable (> S ng/mL) amphetamine. NA indicates enantiomer analysis was not completed because of the low concentration or lack of drug in the sample. Hours post dose represents time since administration of first dose. Subsequent doses administered at daily intervals. Immunoassay result is indicated as POS if the result was positive; all other samples tested negative by immunoassay. * Only a single sample is presented following the last detected amphetamine for each subject. All samples for each of the subjects collected after that time contained no detectable (_> 5 ng/mL) amphetamine. NA indicates enantiomer analysis was not completed because of the low concentration or lack of drug in the sample. Hours post dose represents time since administration of first dose. Subsequent doses administered at daily intervals. Immunoassay result is indicated as POS if the result was positive; all other samples tested negative by immunoassay. * Only a single sample is presented following the last detected amphetamine for each subject. All samples for each of the subjects collected after that time contained no detectable (> 5 ng/mL) amphetamine, NA indicates enantiomer analysis was not completed because of the low concentration or lack of drug in the sample, Hours post dose represents time since administration of first dose. Subsequent doses administered at daily intervals. Immunoassay result is indicated as POS if the result was positive; all other samples tested negative by immunoassay, This results in the same 3:1 proportion of the enantiomers initially following administration of this product. Illicit amphetamine in the U.S. is either only the d-enantiomer or a racemic mixture. These products result in a different enantiomer excretion pattern. The absence of l-enantiomer clearly would demonstrate that Adderall could not be the source of the amphetamine. Initially, racemic amphetamine results in essentially equal amounts of both enantiomers shortly after administration of the drug, followed thereafter by a progressively increasing proportion of the l-enantiomer. As shown in Figure 1 , following the administration of Adderall, the proportion of d-to l-enantiomer did not approach 1:1 while the drug is still being administered on a daily basis. Following secession of dosing, the proportion of l-enantiomer increased, approaching a 1:1 ratio, but not for at least three days following the last dose of the drug. Four of the five subject samples approached, but never actually exceeded, a 1:1 ratio prior to their concentration dropping below the LOD (Figure 1 ). This is consistent with the single dose study, which showed the proportion did not reach 1:1 in four of five subjects until after 132 h post dose.
Other than a single entity mixed enantiomer formulation, the only scenario that would give this proportion would be to administer d-amphetamine and racemic amphetamine in the appropriate proportions and timing to attain those seen in this study. Although unlikely, this possibility should be considered when interpreting results.
To assess the use of racemic versus d-amphetamine, Tetlow and Merrill (22) used enantiomer ratios to monitor compliance with treatment of amphetamine abuse with d-amphetamine. These investigators were able to differentiate use of d-amphetamine from use of racemic amphetamine. In addition, the investigators were able to identify individuals that used both dand racemic amphetamine. In a similar study, George and Braithwaite (23) were also able to differentiate the use of amphetamine sources based on the average ratio of 1-to d-amphetamine.
Conclusions
The current study presents the first published data on the excretion of amphetamine following multi-dose administration of a mixed enantiomer amphetamine product available in the U.S. under a variety of brand names. Evaluation of these data allow for differentiation of the use of this formulation from both common forms of illicit amphetamine. The mere presence of l-enantiomer eliminates the possibility of the individual using medicinal or illicit d-amphetamine. Racemic amphetamine (not legally marketed in the U.S.) yields enantiomer proportions different than those found following the use of mixed amphetamine isomer preparations such as Adderall.
